BPCR — Biopharma Credit Balance Sheet
0.000.00%
Last trade - 00:00- $964.45m
- $958.83m
- $150.03m
- 80
- 81
- 74
- 95
Annual balance sheet for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 193 | 94.7 | 121 | 86.2 | 5.62 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.208 | 10 | 19.8 | 20.3 | 31.8 |
| Total Other Current Assets | |||||
| Total Current Assets | 193 | 105 | 140 | 155 | 37.4 |
| Long Term Investments | |||||
| Total Assets | 1,388 | 1,371 | 1,364 | 1,357 | 1,200 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.39 | 6.34 | 26.3 | 15.9 | 17.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.39 | 6.9 | 26.6 | 15.9 | 17.9 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 1,379 | 1,364 | 1,337 | 1,341 | 1,182 |
| Total Liabilities & Shareholders' Equity | 1,388 | 1,371 | 1,364 | 1,357 | 1,200 |
| Total Common Shares Outstanding |